-
Consumer Insights
NewSpain Apparel Consumer Insights – Who Shops, What do they Shop, How do they Shop and Why do they Shop
Spain Apparel Consumer Insights Report Overview More than 88% of Spanish consumers made an apparel purchase in 2023, however, around a quarter intend to spend less on the category in the next six months amidst concerns of rising inflation. In the same year, many apparel shoppers preferred items in-store over online purchases. It was also observed that consumers chose to spend more on better quality items than purchase cheaper items that will not last. The ‘Spain Apparel Consumer Insights Report’...
-
Track & Monitor
NewEnvironment sustainability in automotive: EV climate control
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the automotive industry’s EV climate control segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Analyst Opinions
NewHealthcare Construction Project Insights and Analytics (Q1 2024)
Healthcare Construction Projects Report Overview The healthcare construction project is valued at $625.4 billion (including all projects from announced to execution stage) in Q1 2024. Factors such as increasing life expectancy, population growth, the surge in lifestyle diseases, and rising healthcare needs will attract investments in healthcare buildings over the coming years. Rising healthcare demand globally will be supported by a strong pipeline of health infrastructure projects. The ‘Healthcare Construction Project Insights and Analytics (Q1 2024)’ research report provides a...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Ulevostinag
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Ulevostinag report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: GSK plc’s Belrestotug
Empower your strategies with our Net Present Value Model: GSK plc's Belrestotug report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Anselamimab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Anselamimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s Eltrekibart
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Eltrekibart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Avalo Therapeutics Inc’s Quisovalimab
Empower your strategies with our Net Present Value Model: Avalo Therapeutics Inc's Quisovalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Verastem Inc’s Avutometinib Potassium
Empower your strategies with our Net Present Value Model: Verastem Inc's Avutometinib Potassium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.